1차 출처 기록
결정급탑라인 결과
Atea AVIR: C-BEYOND 3상, HCV 대상 BEM/RZR의 1차/2차 평가변수 달성
The document reports that the Phase 3 C-BEYOND trial met its primary endpoint of statistical non-inferiority versus SOF/VEL in the mITT population (93.9% vs 94.8% SVR) and all secondary endpoints, including the per-protocol analysis. The 8-week BEM/RZR regimen in non-cirrhotic patients achieved 93.5% SVR, supporting a potential best-in-class profile with shorter duration, low drug-drug interaction risk, and no food effect. NDA submission is now guided for Q2 2027 pending C-FORWARD results.
핵심 사실
출처 발췌
EX-99.1 2 d165663dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027 AT-587 Phase 1 Clinical Trial Advancing for Treatment of Hepatitis E Virus (HEV) Company Holding Conference Call Today at 4:30 pm ET BOSTON, Mass., August 12, 2026 – Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutic